Renalytix Plc ADR Experiences Stock Price Decline Despite Positive Growth Predictions

Renalytix Plc ADR (NASDAQ:RNLX), a market player valued at $15.99 million, saw its stock price decrease by 7.38% to close at $0.32 per share in the last trading session. Approximately 0.19 million shares exchanged hands during this session, which is significantly lower than the company's 10-day average trading volume of 0.51 million shares and 3-month average of 189.02K shares.

Financial Performance and Analyst Ratings

Despite an annual earnings growth rate of 32.00%, the stock has underperformed in comparison to the broader industry over the past 6 months, recording a loss of 91.49%. This places the company's stock significantly below its 52-week high of $4.04 and slightly above the 52-week low of $0.30. Analyst consensus, however, classifies RNLX as a 'Buy' stock, with a solid recommendation rating of 1.00.

Revenue Growth Forecast

Revenue growth estimates for the current and subsequent quarter are 67.90% and 71.40%, respectively, marking a 24.90% growth from the last fiscal year. Analysts anticipate an average revenue of $750k for the current quarter and $1.1 million for the next. However, it's noteworthy that the company's annual earnings growth rate over the past 5 years was negative at -134.64%.

Shareholders and Upcoming Earnings Report

Renalytix Plc ADR, which is expected to release its next earnings report in February, has 37 institutions holding shares, with insiders owning 3.75% and institutions holding 9.95% of the company's shares. The top two institutional shareholders are Gilder, Gagnon, Howe & Co. and Pinnacle Associates, Ltd., holding 2.16% and 1.77% of shares outstanding, respectively. Additionally, the top two mutual funds holding shares are USAA Mutual Fund Tr-Small Cap Stock Fund and Fidelity NASDAQ Composite Index Fund.

Renalytix Plc ADR, incorporated in 2018, is based in New York and develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases, under a license agreement with Mount Sinai Health System and Joslin Diabetes Center Inc.